Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings

Merus NV MRUS has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic breast cancer who had progressed on anti-HER2 antibody-drug conjugates.

• The reported data are from the completed phase 2 study, designed to explore the efficacy of a triplet combination of Zeno.
• Preliminary results for patients treated with the triplet regimen were presented at the American Society of Clinical Oncology 2020 Annual Meeting.
• Updated results from the cohort expansion showed a clinical benefit rate of 49% (18/37 patients).
• Confirmed responses were reported in 10 patients, including two patients with complete response.
• The median duration of response was 4.2 months, including two patients with CR lasting 4.2 and 7.2+ months and eight patients with partial responses (PR) lasting from 2.6 to 12.4 months.
• Median progression-free survival was 5.5 months, seven patients (19%) were censored. At 12 and 24 months, estimated overall survival rates were 73% and 61%, respectively.
• As previously reported, with completing this phase 2 trial, Merus does not plan to advance into a phase 3 trial in metastatic breast cancer without a partner. 
• Related Link: Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers.
• Price Action: MRUS shares 3.97% at $28.25 during the market session on the last check Friday.